<p>投資於能夠扭轉命運的公司的興奮感吸引了一些投機者，因此即使是沒有收入、沒有利潤且業績不佳的公司，也能找到投資者。但現實是，當一家公司每年虧損足夠長的時間後，其投資者通常會承擔這些損失。虧損的公司尚未證明其盈利能力，最終外部資本的流入可能會枯竭。</p>
<p>與此相反，許多投資者更傾向於關注像 <strong>Halozyme Therapeutics</strong>（NASDAQ:HALO）這樣的公司，它不僅有收入，還有利潤。這並不是説該公司提供了最佳的投資機會，但盈利能力是商業成功的關鍵組成部分。</p>
<p>癌症的終結？這 15 只新興的人工智能股票正在開發技術，以便能夠早期識別癌症和阿爾茨海默病等改變生命的疾病。</p>
<h2>Halozyme Therapeutics 的每股收益正在增長</h2>
<p>通常，經歷每股收益（EPS）增長的公司，其股價也應呈現類似趨勢。因此，有很多投資者喜歡購買每股收益增長的公司的股票。在過去三年中，Halozyme Therapeutics 的每股收益年均增長 8.0%。這可能不是特別高的增長，但確實表明每股收益穩步朝着正確的方向發展。</p>
<p>仔細考慮收入增長和息税前利潤（EBIT）利潤率，可以幫助判斷近期利潤增長的可持續性。Halozyme Therapeutics 的股東可以對 EBIT 利潤率從 41% 上升到 54% 以及收入增長感到信心。這兩方面的表現都令人欣慰。</p>
<p>下圖顯示了公司底線和頂線隨時間的變化。點擊圖表查看具體數字。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195"/></p>
<p>NasdaqGS:HALO 每股收益和收入歷史 2025 年 3 月 29 日</p>
<p>查看我們對 Halozyme Therapeutics 的最新分析</p>
<p>幸運的是，我們可以獲取對 Halozyme Therapeutics 未來利潤的分析師預測。您可以自己進行預測，也可以看看專業人士的預測。</p>
<h2>Halozyme Therapeutics 的內部人士與所有股東一致嗎？</h2>
<p>由於 Halozyme Therapeutics 的市值為 79 億美元，我們不期望內部人士持有大量股份。但我們對他們投資於公司的事實感到欣慰。內部人士作為一個整體持有價值 8400 萬美元的股份，他們在公司的成功上有很大的利益。這應該使他們專注於為股東創造長期價值。</p>
<h2>Halozyme Therapeutics 值得在您的關注名單上佔有一席之地嗎？</h2>
<p>如前所述，Halozyme Therapeutics 是一家正在成長的企業，這令人鼓舞。如果這還不夠，還有相當顯著的內部持股水平。這兩個因素是該公司的巨大亮點，應該是您關注名單上的強有力競爭者。不過，仍然需要考慮投資風險的無處不在。<strong>我們發現了 Halozyme Therapeutics 的 1 個警示信號</strong>，理解這一點應該是您投資過程的一部分。</p>
<p>儘管 Halozyme Therapeutics 看起來確實不錯，但如果內部人士購買股份，可能會吸引更多投資者。如果您喜歡看到更多 “有實質性投入” 的公司，那麼請查看這份精心挑選的公司名單，這些公司不僅擁有強勁的增長，還得到了強大的內部支持。</p>
<p><em>請注意，本文討論的內部交易是指在相關司法管轄區內可報告的交易。</em></p>

奧洛茲美醫療

<p>Halozyme Therapeutics（納斯達克代碼：HALO）因其收入和利潤增長而受到關注，成為潛在投資對象。過去三年，該公司的每股收益（EPS）年均增長 8.0%，息税前利潤（EBIT）利潤率從 41% 上升至 54%。內部人士持有 8400 萬美元的股份，表明他們對長期價值創造的承諾。儘管公司前景看好，但投資者仍需對潛在風險保持謹慎，包括一個已識別的警示信號。總體而言，Halozyme Therapeutics 可能是觀察名單上的強有力候選者</p>

<p>The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. A loss-making company is yet to prove itself with profit, and eventually the inflow of external capital may dry up.</p>
<div class="lb-trans"><p>投資於能夠扭轉命運的公司的興奮感吸引了一些投機者，因此即使是沒有收入、沒有利潤且業績不佳的公司，也能找到投資者。但現實是，當一家公司每年虧損足夠長的時間後，其投資者通常會承擔這些損失。虧損的公司尚未證明其盈利能力，最終外部資本的流入可能會枯竭。</p>
</div><p>In contrast to all that, many investors prefer to focus on companies like <strong>Halozyme Therapeutics</strong> (NASDAQ:HALO), which has not only revenues, but also profits. Now this is not to say that the company presents the best investment opportunity around, but profitability is a key component to success in business.</p>
<div class="lb-trans"><p>與此相反，許多投資者更傾向於關注像 <strong>Halozyme Therapeutics</strong>（NASDAQ:HALO）這樣的公司，它不僅有收入，還有利潤。這並不是説該公司提供了最佳的投資機會，但盈利能力是商業成功的關鍵組成部分。</p>
</div><p>The end of cancer? These 15 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.</p>
<div class="lb-trans"><p>癌症的終結？這 15 只新興的人工智能股票正在開發技術，以便能夠早期識別癌症和阿爾茨海默病等改變生命的疾病。</p>
</div><h2>Halozyme Therapeutics' Earnings Per Share Are Growing</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 的每股收益正在增長</h2>
</div><p>Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Over the last three years, Halozyme Therapeutics has grown EPS by 8.0% per year. That might not be particularly high growth, but it does show that per-share earnings are moving steadily in the right direction.</p>
<div class="lb-trans"><p>通常，經歷每股收益（EPS）增長的公司，其股價也應呈現類似趨勢。因此，有很多投資者喜歡購買每股收益增長的公司的股票。在過去三年中，Halozyme Therapeutics 的每股收益年均增長 8.0%。這可能不是特別高的增長，但確實表明每股收益穩步朝着正確的方向發展。</p>
</div><p>Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. Halozyme Therapeutics shareholders can take confidence from the fact that EBIT margins are up from 41% to 54%, and revenue is growing. That's great to see, on both counts.</p>
<div class="lb-trans"><p>仔細考慮收入增長和息税前利潤（EBIT）利潤率，可以幫助判斷近期利潤增長的可持續性。Halozyme Therapeutics 的股東可以對 EBIT 利潤率從 41% 上升到 54% 以及收入增長感到信心。這兩方面的表現都令人欣慰。</p>
</div><p>The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.</p>
<div class="lb-trans"><p>下圖顯示了公司底線和頂線隨時間的變化。點擊圖表查看具體數字。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195" alt="" original-src="https://images.simplywall.st/asset/chart/7931206-earnings-and-revenue-history-1-dark/1743260321195"/></p>
<p>NasdaqGS:HALO Earnings and Revenue History March 29th 2025</p>
<div class="lb-trans"><p>NasdaqGS:HALO 每股收益和收入歷史 2025 年 3 月 29 日</p>
</div><p>See our latest analysis for Halozyme Therapeutics</p>
<div class="lb-trans"><p>查看我們對 Halozyme Therapeutics 的最新分析</p>
</div><p>Fortunately, we've got access to analyst forecasts of Halozyme Therapeutics' <em>future</em> profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.</p>
<div class="lb-trans"><p>幸運的是，我們可以獲取對 Halozyme Therapeutics 未來利潤的分析師預測。您可以自己進行預測，也可以看看專業人士的預測。</p>
</div><h2>Are Halozyme Therapeutics Insiders Aligned With All Shareholders?</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 的內部人士與所有股東一致嗎？</h2>
</div><p>Since Halozyme Therapeutics has a market capitalisation of US$7.9b, we wouldn't expect insiders to hold a large percentage of shares. But we are reassured by the fact they have invested in the company. With a whopping US$84m worth of shares as a group, insiders have plenty riding on the company's success. This should keep them focused on creating long term value for shareholders.</p>
<div class="lb-trans"><p>由於 Halozyme Therapeutics 的市值為 79 億美元，我們不期望內部人士持有大量股份。但我們對他們投資於公司的事實感到欣慰。內部人士作為一個整體持有價值 8400 萬美元的股份，他們在公司的成功上有很大的利益。這應該使他們專注於為股東創造長期價值。</p>
</div><h2>Does Halozyme Therapeutics Deserve A Spot On Your Watchlist?</h2>
<div class="lb-trans"><h2>Halozyme Therapeutics 值得在您的關注名單上佔有一席之地嗎？</h2>
</div><p>As previously touched on, Halozyme Therapeutics is a growing business, which is encouraging. If that's not enough on its own, there is also the rather notable levels of insider ownership. These two factors are a huge highlight for the company which should be a strong contender your watchlists. It's still necessary to consider the ever-present spectre of investment risk. <strong>We've identified 1 warning sign</strong> with Halozyme Therapeutics , and understanding this should be part of your investment process.</p>
<div class="lb-trans"><p>如前所述，Halozyme Therapeutics 是一家正在成長的企業，這令人鼓舞。如果這還不夠，還有相當顯著的內部持股水平。這兩個因素是該公司的巨大亮點，應該是您關注名單上的強有力競爭者。不過，仍然需要考慮投資風險的無處不在。<strong>我們發現了 Halozyme Therapeutics 的 1 個警示信號</strong>，理解這一點應該是您投資過程的一部分。</p>
</div><p>Although Halozyme Therapeutics certainly looks good, it may appeal to more investors if insiders were buying up shares. If you like to see companies with more skin in the game, then check out this handpicked selection of companies that not only boast of strong growth but have strong insider backing.</p>
<div class="lb-trans"><p>儘管 Halozyme Therapeutics 看起來確實不錯，但如果內部人士購買股份，可能會吸引更多投資者。如果您喜歡看到更多 “有實質性投入” 的公司，那麼請查看這份精心挑選的公司名單，這些公司不僅擁有強勁的增長，還得到了強大的內部支持。</p>
</div><p><em>Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.</em></p>
<div class="lb-trans"><p><em>請注意，本文討論的內部交易是指在相關司法管轄區內可報告的交易。</em></p>
</div>

現在是時候將奧洛茲美醫療（NASDAQ:HALO）加入你的觀察名單了嗎？